Q-omics provides the consensus-scored LINC01405 profile across patient tissues and cancer cell-line models. LINC01405 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01405 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC01405 RNA expression shows 9,826 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where LINC01405 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01405 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01405 survival associations across molecular data types. LINC01405 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01405 RNA expression–survival associations across cancer types. High LINC01405 expression shows unfavorable associations in KIRC, UVM, BRCA, MESO, LIHC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01405 RNA expression.
This table summarizes LINC01405 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01405. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01405 shows lower tumor expression in HNSC, THCA and KICH and higher tumor expression in LUSC and CHOL. The HNSC box plot shows higher LINC01405 RNA expression in normal versus tumor tissue (log2 FC = −1.262, t-test p = .002).
This table shows molecular features associated with LINC01405 in patient tissues and cancer cell lines. In patient samples, LINC01405 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
